NOXOPHARM LIMITED CLOSES OVERSUBSCRIBED IPO

SYDNEY, Australia, July 20, 2016 /Medianet International-AsiaNet/--

* Noxopharm is a clinic-ready Australian biotech with a current focus on a drug product technology offering the possibility of less-damaging chemotherapy for cancer patients and those who are unable to tolerate standard treatments, and also for patients with cancers such as pancreatic cancer where survival prospects remain poor. * IPO raised $A6 million - strongly supported by institutional, retail and high net worth investors along with general public investors with an interest to see a change in current standard of-care cancer treatments * ASX - Listing date to be advised http://mrem.bernama.com/viewsm.php?idm=27188